PharmaLectures.com

Courses › Country and business playbooks › Selling into Europe as a finished-dose generic company from Japan

Selling into Europe as a finished-dose generic company from Japan

Your team files European generic dossiers that clear validation the first time.

  • 12 audio modulesthree lengths each
  • 2 h to 10 hbriefing to expanded
  • Workbook, transcript, certificateand a recorded quiz per module
  • Japan, Finished-dose generic companywho it is written for

Why this training matters

Your dossier reaches a European assessor and the questions come back: the reference product does not fit Article 10(1), and the Module 3 batch data do not match the Module 5 bioequivalence study. Your team spends months answering instead of launching, and the launch date moves again.

What changes after this course

Your team picks the procedure, builds the dossier and answers the inspector's question from the page instead of from a consultant. You hold a certificate for every learner and a training record for each person, backed by a recorded multiple-choice questionnaire per module.

Watch the pitch

3:43 on how an audio course is bought, listened to and recorded. Full screen, one click.

Watch the pitch3:43, full screen, one click

What this course gives your people

Your regulatory affairs team chooses between the Centralised, Decentralised and Mutual Recognition Procedures without a round of emails to legal. They file a Common Technical Document that follows Article 10(1) of Directive 2001/83/EC, with Module 1 in order and Module 2 written for the assessor. The questions that used to come back after validation stop coming.

Factory managers and quality staff open EudraLex Volume 4 and know which chapter or annex answers the inspector's question. When a national competent authority walks the site, the answer comes with a reference, not a promise to reply later. The deficiency list is shorter, and the site stays in control of the visit.

In the commercial department, the market access director builds the value dossier knowing how external reference pricing carries one country's price into the next. The team reads a tender notice against what the group purchasing organisation will score. Pharmacy chains and wholesalers hear a case for your generic, not a price list.

Pharmacovigilance staff send adverse drug reaction reports to EudraVigilance inside the deadline, and the Qualified Person for Pharmacovigilance checks the system against Good Pharmacovigilance Practices before an inspector does. Periodic safety update reports and variations go in on the date, so no marketing authorisation is put at risk by a missed submission.

Who needs this training

  • Regulatory Affairs Manager

    Faces a blank Common Technical Document and must decide between the Decentralised and Mutual Recognition Procedure for a generic, knowing a wrong choice shows up months later.

  • Head of Quality Assurance

    Is asked by an inspector from a national competent authority how a process meets EudraLex Volume 4, and needs the chapter and the answer on the spot.

  • Market Access Director

    Prepares a value dossier for a new member state and must stop a low price there from pulling down prices in markets already launched.

  • Qualified Person for Pharmacovigilance

    Must show that every adverse drug reaction reaches EudraVigilance on time, and finds the gaps in the pharmacovigilance system master file before an inspection does.

  • Business Development Manager, Europe

    Sits across the table from a European partner and needs to read the direct question, the silence and the disagreement correctly, then keep the deal alive.

Roles: Owner, CEO and board, Business development and export sales, Regulatory affairs, Quality assurance and Qualified Person

Businesses: Finished-dose generic company

Countries: Japan

Selling into: Europe and the UK

Courses are in English. Other languages on request.

After this course your people can

  1. Select the Marketing Authorisation Application procedure that fits a given finished-dose generic and justify the choice in writing.
  2. Assemble a Common Technical Document dossier with Modules 1 to 5 in the order assessors expect.
  3. Design a bioequivalence study against a European reference product and say when dissolution data supports it.
  4. Match a site procedure to the right chapter or annex of EudraLex Volume 4 during an inspection.
  5. Report an adverse drug reaction to EudraVigilance inside the regulatory deadline.
  6. Write a value dossier that anticipates both external and internal reference pricing.
  7. Classify a variation and schedule periodic safety update reports without outside help.

What the company gets

  • Your staff answer basic questions about European Medicines Agency procedures themselves, so consultant time goes to the hard cases only.
  • Your site meets the inspector with a clear answer to each EudraLex Volume 4 question, which lowers the risk of a major deficiency report that halts production.
  • Reference pricing mistakes are caught in the dossier, before one country's price lowers your margin in several others.
  • Variations and periodic safety update reports leave on schedule, so your marketing authorisations stay in good standing.
  • Every learner finishes with a certificate and a training record you can show an auditor.

The evidence: questionnaire, training record, certificate

EU GMP Chapter 2, section 2.11, and 21 CFR 211.25 both ask for training that is documented and shown to work. This is what each learner leaves behind.

A recorded questionnaire per module

Every one of the 12 modules ends with a multiple-choice questionnaire. The result is recorded per person with a timestamp, whichever of the three lengths the person listened to.

A per-person training record

The export lists each learner, each module, the result and the date, which is the training record EU GMP Chapter 2 and 21 CFR 211.25 ask you to keep and the first thing an inspector asks for.

A certificate per learner

Name, company, course, hours, the guideline version taught and the date. It documents in-company training; it is not a professional qualification or an accreditation.

Your pass mark, your rule

There is no fixed pass mark. Your quality or human-resources manager decides what counts as passed and when a module is retaken, exactly as your training procedure says.

Delivered within 72 hours of payment, with the workbook, the full transcript and a source for every fact in the audio.

How long it takes, by who is listening

Nobody spends a day in a classroom. Every module exists in three lengths; a person takes the length their role needs, and every length ends with the same recorded questionnaire, so the training record is complete either way.

Briefing2 h10 min a module, for executives, sales and anyone who must know the rules, not run them
Standard5 h25 min a module, for regulatory, quality and business-development staff
Expanded10 h50 min a module, for technical staff who run the procedure day to day
Who takes this courseLengthTotal time
Owner, CEO and boardBriefing2 h
Business development and export salesBriefing2 h
Regulatory affairsStandard5 h
Quality assurance and Qualified PersonStandard5 h

Course outline: 12 modules

12 modules. Under each title are the three things the listener can do afterwards; the audio itself runs 10 to 50 minutes depending on the length chosen.

  1. 1Size up the European market and its member states before you commit

    • Why the European Union is many markets, and which member states suit a first Japanese generic launch.
    • The line between what the European Medicines Agency assesses and what each national authority still decides.
    • What to do when a national competent authority reads a rule differently from the agency.
  2. 2Apply Directive 2001/83/EC Article 10(1) to each of your generics

    • Why the reference medicinal product you pick sets the date your generic can be filed and sold.
    • How to show your product is a generic without repeating the reference product's clinical trials.
    • When Article 10(1) fits your product and when a different legal basis in Directive 2001/83/EC applies.
  3. 3Choose the right Marketing Authorisation Application procedure first time

    • When the Centralised Procedure is open to your generic and when you must file nationally.
    • How the Mutual Recognition Procedure turns one approval into approvals in other member states.
    • Where the Decentralised Procedure loses time, and how your timetable avoids those stops.
  4. 4Build a Common Technical Document dossier assessors can follow

    • How to lay out Module 1 so the assessor finds the forms and product information at once.
    • The Module 2 summaries that answer an assessor's first questions before they are asked.
    • What goes in Modules 3 and 5, and why you need no new Module 4 studies under Article 10(1).
  5. 5Align your drug product specifications with European quality standards

    • How to run stability studies to the Q1A guideline so European assessors accept the data.
    • The gaps in process validation that draw an assessor's question, and how to close them before filing.
    • Which drug substance and drug product specification items assessors check first.
  6. 6Design bioequivalence studies that competent authorities accept

    • How to design a bioequivalence study against a European reference product, not a Japanese one.
    • When an in vitro dissolution test supports your bioequivalence case and when it cannot stand alone.
    • What to do when high intra-subject variability puts your study result in doubt.
  7. 7Pass European Good Manufacturing Practice audits against EudraLex Volume 4

    • How to read EudraLex Volume 4 so your procedures answer what the inspector will ask.
    • What an inspector from a national competent authority looks at as they walk your site.
    • The corrective actions that close the most common Good Manufacturing Practice deficiencies.
  8. 8Set up a pharmacovigilance system that meets EudraVigilance rules

    • How your Qualified Person for Pharmacovigilance spots a compliance gap before an inspector does.
    • The reporting deadlines for adverse drug reactions that EudraVigilance expects you to meet.
    • What the pharmacovigilance system master file must hold for the Marketing Authorisation Holder.
  9. 9Submit pricing and reimbursement dossiers that hold across Europe

    • Why a price set in one country can pull down your price in another through external reference pricing.
    • The evidence a value dossier needs before a payer agrees to reimburse your generic.
    • What to do when internal reference pricing groups your product with cheaper alternatives.
  10. 10Win market access and European public healthcare tenders

    • How to present your finished-dose generics to pharmacy chains and wholesalers so they stock them.
    • The criteria group purchasing organisations weigh when they award a hospital contract.
    • What to have ready before you enter a public healthcare tender, so the deadline does not catch you.
  11. 11File variations and periodic safety update reports on schedule

    • How to classify a variation to your Marketing Authorisation yourself, without calling a consultant.
    • The schedule for periodic safety update reports, so no submission date catches you out.
    • What triggers a mandatory change to your product information and labelling.
  12. 12Negotiate with European pharmaceutical partners and keep the deal moving

    • How European negotiation habits differ from Japanese corporate tradition, and where that causes friction.
    • The communication habits that build trust with a European business development team.
    • How to voice disagreement in a European meeting and keep the partnership moving.
The founders

One of us was inspected. The other one pays for the training.

Every claim below is sourced on the about page: the medicines register, the Lithuanian Pharmaceutical Union board list, the university directory.

Justina Krukonytė-Racz

Justina Krukonytė-Racz

Co-founder. Licensed pharmacist.

GDPResponsible PersonWarehouse & logistics

Licensed pharmacist. Responsible Person at Tamro (PHOENIX group), where she led the GDP set-up of the distribution centre.

The Responsible Person is the named person the regulator holds accountable for every pallet that leaves the building.

She writes the modules around the procedures a GDP inspection checks. Board member of Lithuanian Pharmaceutical Union.

Listed in the Lithuanian medicines register as Pharmacist.

Prof. Ben Racz

Prof. Ben Racz

Co-founder. Builds the platform and is responsible for delivery, records and pricing.

Platform & deliveryQuantitative researchCarnegie Mellon

He was Professor of the Practice at the College of Engineering at Carnegie Mellon University, where he taught Advanced Quantitative Finance and Algorithmic Trading to MSc students.

He is the founder and Managing Director of Algorithmic Sciences, a scientific research and consulting firm. Earlier he co-founded a data-driven growth consultancy, a data-science based wholesale trading company and an information security firm.

More about Ben at benracz.com

Questions about this course

Is there a certificate?

Yes. Every learner who finishes the course receives a certificate in their own name, and every module ends with a recorded multiple-choice questionnaire, so the certificate sits on top of a per-person training record. The certificate documents in-company training; it is not a professional qualification or an accreditation, and your quality or human-resources manager sets the pass mark and decides when a module is retaken.

How long does the course take?

12 modules, each in three lengths: a 10-minute briefing, a 25-minute standard run and a 50-minute expanded walk-through. The whole course takes 2 h in the briefing length and 10 h in the expanded length. People take the length their role needs, and every length ends with the same recorded questionnaire, so the training record is complete either way.

Who should take this course?

It is written for Japan, Finished-dose generic company. Owners, managers and sales staff hear the briefing length, regulatory, quality and business-development staff take the standard run, and the people who run the procedure every day get the expanded version. One licence covers one named person on this course for a year, so the same title can be rolled out across a whole team at once.

Is this training accepted as a GMP training record by an auditor?

EU GMP Chapter 2 and 21 CFR 211.25 require documented, effective training, and that is what the course produces: a recorded multiple-choice result per module and per person, a certificate per learner and a transcript of what was taught. No provider can promise acceptance by a specific inspector; the record is built to answer what inspectors ask for, and your quality manager decides the pass mark.

How is it delivered and how fast?

The course arrives as audio files with a companion workbook, a full transcript and the questionnaire per module, within 72 hours of your payment arriving. You host the files on your own system or share them as you like; there is no platform to log into and no learner management system to set up. The free sample module arrives on request, before any purchase.

What does it cost per learner?

The list price is 9 euros per module, per learner, per year, so this course is 108 euros for one person for twelve months. The price per learner falls as more people take the same course: 10 learners pay 10 percent less and the discount keeps growing to 50 percent at 1000 learners. Type a number on the price panel and the yearly total appears.

Get this course for your team

One licence is one person on this course for a year. All three lengths, the workbook, the certificate and the training record are included in every purchase. Pick how many people, add it to the cart, and you have an invoice in your inbox.

Free sample module

Hear one full module before you spend a cent. Send your company and the role you want trained, and a complete sample module comes back with its workbook and transcript.

Connect on WhatsApp

or email [email protected], or ask for a written quote for your team